Antibodies derived from scleroderma patients positive for the extractable 70-kDa antigen were shown to react with topoisomerase I. Topoisomerase I was identified by molecular size and by antibody inhibition of the topoisomerase I-specific relaxation of supercoiled plasmid DNA. By using in situ localization by indirect fluorescence, we found topoisomerase I preferentially located in the centromeric regions of the mouse G2-phase cells and chromosomes, while the distribution in human cells is much more dispersed. Moreover, comparison of a published consensus sequence for topoisomerase I binding with mouse satellite DNA revealed a high degree of homology. The localization of topoisomerase I in the centromeres of mouse cells in the later part of the cell cycle and prior to anaphase suggests functional involvement in mitosis.
scleroderma frequently contains antibodies to nuclear antigens that can be of diagnostic value. Sera reacting with the kinetochore are typical for patients with calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia (CREST) syndrome (1) (2) (3) (4) . Patients with diffuse scleroderma characteristically have a high incidence of antibodies reacting with an extractable nuclear antigen of =70 kDa (Scl-70) (5, 6) . We found the antigen to be significantly larger than reported (5, 7) . Most reports indicate a diffuse immunofluorescent staining with enhanced nucleolar localization (7) when cultured cells react with these antibodies. Our initial observations indicated diffuse nuclear staining with some cells exhibiting a speckled pattern. In mouse 3T6 cells, the pattern was reminiscent of kinetochores, suggesting centromeric localization. We therefore set out to characterize the antigen and determine its precise localization.
Sera from patients with CREST syndrome react with the kinetochore and are generally referred to as anti-centromeric antibodies (1) (2) (3) (4) . Within this paper, we make the distinction between the kinetochore, as identified by CREST sera, and the underlying centromere. The term kinetochore denotes the electron-dense structure to which microtubules attach within the mitotic chromosome, as well as the structures found in interphase cells, termed prekinetochores (8) . The centromere refers to the heterochromatic DNA located at the mitotic chromosome constriction point between the two kinetochores, as well as the heterochromatic DNA between the prekinetochores in interphase and G2 phase mouse cells.
MATERIALS AND METHODS
Preparation of Topoisomerase I-Containing Extract. A crude nuclear extract from HeLa cells containing topoisomerase activity was prepared according to the method of Liu (9) .
Topolsomerase I Assay. Topoisomerase I activity was monitored by assaying the relaxation of superhelical DNA (9, 10) . Antibody inhibition assays were performed by preincubating the HeLa cell extract with various dilutions of DEAEAffi-Gel Blue-purified IgG for 1 hr at 4°C. The DNA substrate was added and the reaction mixture was incubated at 30°C for 30 min.
Immunofluorescence and Immunoblotting. Various antisera positive for Scl-70 by the immunodiffusion assay were used at a dilution of 1:1000. Mouse 3T6 cells were grown to semiconfluency on round glass coverslips in minimal essential medium (MEM) with 10% calf serum and fixed for 5 min in 3% freshly prepared paraformaldehyde in phosphatebuffered saline (PBS) containing 1 mM Mg2" and Ca2+ for 5 min followed by treatment with sodium borohydride (1 mg/ml), PBS wash, and permeabilization in 1% Triton X-100 in PBS for 2 min. The cells were then processed for immunofluorescence as described (11) .
To determine the position of the Scl-70 antigen relative to the kinetochore, "double labeling" was performed. For this purpose, the cells were first incubated with Scl-70 antiserum, followed by biotinylated goat anti-human antibodies and fluorescein-conjugated avidin. The cells were then sequentially incubated with anti-kinetochore antibody, biotinylated anti-human antibodies, and rhodamine-labeled avidin. Because the rhodamine label can associate with both antibodyantigen complexes, the localization of both antigens can be photographed simultaneously through the rhodamine filter. Fluorescein, however, labels only the Scl-70 antigen. Gel electrophoresis and immunoblotting were performed as described (11) except that 10-15% polyacrylamide gels were used to separate the proteins of whole HeLa cells or isolated nuclei (12) . For approximation of the isoelectric point, two-dimensional gel electrophoresis was performed as described (13) . Affinity purification of antibodies from nitrocellulose was performed according to Smith and Fisher (14) . number of cells had large speckles, which were observed mostly in the larger nuclei (Fig. la) . The large speckles corresponded to higher DNA concentrations, as indicated by the corresponding image after Hoechst 33258 staining (Fig.  lb) . The heterochromatic DNA was often attached to nucleoli and contained the kinetochore ( Fig. 1 c and d ). Double staining of 3T6 cells (i.e., first with Scl-70 antibodies and fluorescein labeling followed by anti-kinetochore antibodies and rhodamine labeling) clearly indicated that the large heterochromatic areas contained higher concentrations of the Scl-70 antigen and, on the surfaces of these areas, the prekinetochores ( Fig. 1 e-g ). These areas are therefore expected to contain centromeric DNA. Very early prophase cells showed the same distribution of anti-Scl-70 antibodypositive areas ( Fig. 1 h and i) . During later prophase, the centromere stained intensely with the anti-Scl-70 antiserum in >70% of all prometaphase cells ( Fig. lj and k) . In the rest of the prophase cells shown in Fig. 1 (1 and m) , the chromosomes appeared free of antigen but staining is present within the interchromosomal space. Also shown in this micrograph are two nuclei with the characteristic diffuse staining excluded from the nucleolar area. Later in metaphase, the centromeric area again reacts with the anti-Scl-70 antibodies (not shown). We have not seen staining of centromeres in early anaphase chromosomes ( Fig. 1 p and q) . None of the early G1 cells recognizable by the presence of the Flemming body showed the heterochromatic DNA area reacting with anti-Scl-70 antibodies. Control human antibodies did not react with the centromere.
RESULTS
The possibility that two different nuclear antibodies were present in the antiserum was considered. To find a centromere-specific, as opposed to kinetochore-specific, antibody was intriguing; however, an IgG that was affinitypurified from the only band reacting on nitrocellulose blots (see below) stained the centromere ( Fig. 1 n and o) . The possibility that the observed higher anti-Scl-70 antibody binding levels was the result of higher DNA concentration in these areas was excluded based on the absence of increased staining intensity over crossed chromosomes ( Fig. lj and k,  arrows) and by the differential staining along a chromosome that had separated from the spindle ( Fig. 1 r and s) . The possibility that the antibody specifically stains repetitive sequences in the mouse centromere is excluded since 30% of the prophases showed no centromeric reactivity.
The degree ofpreferential staining of centromeres in mouse chromosomes with anti-Scl-70 antiserum was not observed in human WI-38 chromosomes ( Fig. 1 t and u) . Occasionally, slight enrichment over the centromere could be recognized, but it was difficult to document because of the intense staining of the rest of the chromosomes. Larger and presumably G2-phase nuclei had a speckled appearance, but they could not be correlated with heterochromatic sites.
Determination of the Molecular Size and Isoelectric Point of the Scl-70 Antigen. The Scl-70 antigen is an abundant nuclear antigen susceptible to proteolysis (see refs. 5 and 7). To avoid degradation of the nuclear antigen, total HeLa cell proteins were separated on 10-15% NaDodSO4 gels after solubilization in 2% NaDodSO4 and reducing agents. Several sera from patients with progressive systemic sclerosis that were positive for Scl-70 antigen by the double-diffusion assay with a prototype anti-Scl-70 antiserum were tested by immunoblotting. As expected, visualization was titer dependent. All antisera shown in Fig. 2 polyacrylamide gels, electroblotted, and probed with different antisera known to contain antibodies to the extractable nuclear antigen Scl-70 except lane 1, which came from a progressive systemic sclerosis patient with a homogenous anti-nuclear antibody pattern, and lane 7, a control serum. All sera had been diluted 500 times. Lanes 2-6 were probed with anti-Scl-70 antisera of decreasing titers (1:4000-1:160).
Only a single band at 100-105 kDa reacted in most antisera tested. A few antisera contained additional bands in the 30-kDa range (not shown). Immunoblots of isolated nuclei, nuclear matrix, and intact cells all reacted at -100 kDa (not shown). The previous size estimation of 86 kDa for the nuclear matrix bound Scl-70 antigen had obviously been too low (7) . Isolated nuclei as well as total cell homogenate, if left at room temperature over several hours, showed reactivity of several bands with higher mobilities (not shown). Fig. 2 (lane 1) was probed with antiserum from a progressive systemic sclerosis patient showing identical immunofluorescent images as antisera containing anti-Scl-70 antibodies but without any recognizable titer against the Scl-70 extractable antigen. A different as yet undetermined set of three proteins was recognized. Material in lane 8 was incubated with one of the control sera and shows, at the level of sensitivity used, no background reactivity.
We determined the isoelectric point (pI) for the 100-kDa antigen by comparative two-dimensional gel electrophoresis using lamin A (pI 7.1), vimentin (pI 5.3), and heterogeneous ribonucleoprotein core protein A2 (pI 8.4) (15) as pI markers (Fig. 3) . The 100-kDa antigen is basic and has a pI of %8.4. Of the abundant and labile nonhistone nuclear proteins, topoisomerase I had similar physical properties. We therefore used a topoisomerase I assay to determine whether the antibodies against the Scl-70 antigen could block topoisomerase I activity.
Inhibition of Topoisomerase I Activity. The capability of the Scl-70 sera to inhibit topoisomerase I activity was ascertained by the ability of purified IgG to inhibit the relaxation of superhelical DNA (9) . IgG was purified on DEAE-Affi-Gel Blue to prevent nonspecific inhibition of topoisomerase I (16) . Electrophoresis was performed under conditions in which form II DNA was separated from the relaxed form I DNA (10) . The anti-Scl-70 antibodies had a complete inhibitory effect when 80 ng (4,tg/ml) or more of IgG was used in the assay (Fig. 4) . When 20 ng (1 gg/ml) of IgG was used, only partial inhibition ofrelaxation was observed. Normal IgG had no effect on the relaxation of superhelical DNAs by topoisomerase I even at concentrations of 100 pug/ml. Therefore, the Scl-70 antisera contain topoisomerase I binding activity.
DISCUSSION
Evidence That Anti-Scl-70 Antibodies Bind to Topoisomerase I. An abundant nuclear protein recognized by sera from patients with connective tissue disease has been reported to be uniquely associated with diffuse scleroderma (5) and to have prognostic value in the diagnosis of this disease (6, 7) . The size of the extractable nuclear antigen has been determined to be :70 kDa and tends to be proteolytically cleaved (7) . We determined that the intact size of the Scl-70 antigen from isolated nuclei and from total HeLa cells is the same at 100-105 kDa. The isoelectric point of f8.4 was determined by comparing the 100-kDa antigen with several marker proteins. The localization in the nucleus and the rather basic pI suggests possible nucleotide interaction. Because the smaller Scl-70 antigen was extractable, whereas the larger component was bound to chromatin and a nuclear matrix fraction, it is assumed that the Scl-70 antigen is a fragment of the larger protein (7) .
Among the known chromatin-bound proteins of %100 kDa, only topoisomerase I is easily degraded to smaller still enzymatically active fragments (17, 18) . The possibility that the 100-kDa antigen is topoisomerase I was tested by using a relaxation assay in which the ability of the antibodies to inhibit conversion of supercoiled plasmid DNA into a relaxed form was tested. IgG from different progressive systemic sclerosis patients with anti-Scl-70 antibodies inhibited this relaxation but control serum or antiserum from progressive systemic sclerosis patients without these antibodies did not. Based on the alkaline pI [topoisomerase I binds to phosphocellulose columns (9)], similarities in molecular size and the ability of the antibodies to functionally inhibit topoisomerase I, we conclude that the IgG from antiserum of progressive systemic sclerosis patients reactive with the Scl-70 extractable antigen are topoisomerase I specific. Furthermore, the Scl-70 antigen is a proteolytic breakdown product of this enzyme.
Localization of Topoisomerase I in Mouse 3T6 Cells. Topoisomerase I antibodies react in situ with chromatin in a diffuse pattern, although specific localization on the nucleolus has been reported (7, 16) . We observed that most nucleoli were unlabeled, and obvious G1 phase cells (cells connected by the midbody) showed no speckled pattern. A higher accumulation of topoisomerase I was detected in centromeric regions, as judged from kinetochore distribution on the surface of high-density DNA areas in the nucleus. In some cells, nucleoli were involved because of the association with heterochromatic DNA on their surfaces. From the size of these nuclei and the similar distribution of topoisomerase I accumulation in the centromeric region of early prophase cells, we judge that the larger nuclei are in G2 phase; also, many showed a duplication of the kinetochore. Double labeling with both anti-kinetochore and anti-topoisomerase I antibodies showed that the centromeric region, as opposed to the kinetochore, was labeled by anti-topoisomerase I antibodies. Some of the centromeric regions seemed aggregated, indicated by the clustering of kinetochores (see also ref. 19 ). We therefore assume a functional association of topoisomerase I with the centromeric region in G2 phase cells and with chromosomes before anaphase.
About 30% of late prophase cells showed no enrichment of label at the centromere, although interchromosomal spaces appeared to be labeled. The significance of this observation, if any, remains unclear. The high concentration of label before and after this state may not necessarily reflect high activity but, instead, may indicate inhibition of activity and concomitant accumulation by occupation of any potential and available sites. This interpretation assumes that topoisomerase I is released from its site after a nicking-closing reaction but remains bound when either the nicking or the closing function is inhibited by factors on the DNA or by specific modification of the topoisomerase I (e.g., phosphorylation activates the enzyme) (20) . Specific topoisomerase I-requiring functions at precise stages of the cell cycle may have to be postulated that coincide with the disappearance of the enzyme from the centromeric region.
Function of Topoisomerase I inl Mitosis. Topoisomerase I binding to mouse centromeres suggests a specific association at this area, possibly at the DNA level. A topoisomerase I binding sequence has been recently reported (21) . The sequences involved in topoisomerase I binding conform to the consensus:
AGACTTAGAGAAAAT.
We therefore searched for sequence homology within cloned satellite DNA (22) . Three regions of homology were present in a 74-nucleotide fragment of mouse satellite DNA (Fig. 5) . Very high homology was found on both sides of the consensus TT dinucleotide, providing circumstantial evidence for a potential binding site. However, two consecutive T residues, a known high-frequency cut site for topoisomerase I, are not represented in this mouse satellite sequence.
Topoisomerase I activity has been implicated in DNA replication, RNA transcription, genetic recombination, DNA catenation, and decatenation (for reviews, see refs. [23] [24] [25] . We have demonstrated that topoisomerase I is located at the centromere during mitosis in the mouse chromosome, suggesting the involvement at the centromere. Studies with yeast indicate that topoisomerase II is absolutely required for chromosome segregation during mitosis (26, 27) . However, topoisomerase I mutants grow normally, making it difficult to assess the function of topoisomerase I in yeast mitosis. Topoisomerase I may serve to maintain specific chromatin configuration within the centromeric DNA. A specific chromatin organization has been proposed for the kinetochoreassociated DNA fibrils (28) . The enzyme may function as a single-strand nicking and closing enzyme to allow chromatid separation at the beginning of anaphase. Although topoisomerase II may be required for chromosome separation in yeast, this does not exclude additional involvement of topoisomerase I in this function in higher eukaryotes.
After submission of this paper, Shero et al. reported that high titers of autoantibodies to topoisomerase I are found in sera from scleroderma patients (Scl-70) (29) .
